Share
تاثير استخدام عقار الميتفورمين منفردا او استعماله مجتمعا مع عقار كلكلزايد على مستوى الاومنتين - 1 - في مرضى داء السكري من النوع الثاني == Effects Of Metformin Alone Or In Combination With Gliclazide On Serum Omentin - 1 Levels In Patients With Type 2 Diabetes Mellitus
Author name:
سمر محمد غني سليمان
Supervisor name:
علي اسماعيل عبد الله محمد | حيدر فاضل الربيعي
General topic:
Medicine
Specific topic:
Medicines and Toxins
Degree:
Master
University:
Mustansiriyah University - Faculty Of Medicine - Pharmacology Department
Language:
English
University location:
Baghdad
First pages:
19T1181 - p.pdf
Abstract:
اجريت الدراسة الحالية لبحث التاثير العلاجي لاستخدام عقار الميتفورمين منفردا او استعماله مجتمعا مع عقار كلكلزايد على مستوى الاومنتين - 1 - باالاضافة الى المؤشرات الحيوية الاخرى في مرضى داء السكري من النوع الثاني من اجل تقييم ما اذا كان الجمع بين العقارين ( | Background : Omentin is a newly identified adipokine, which is highly expressed in visceral adipose tissue, in which omentin - 1 is the main isoform in human circulation, associated with cardio - metabolic disturbances. So considering the impact of anti - diabetic drug on omentin - 1 levels may provide adjuvant strategy to protect diabetic patients against clinical hazards.Aim of the study : The present study aimed to investigate the influence of treatment with metformin alone or in combination with gliclazide on the level of serum omentin - 1, in addition to the other biomarkers adopted in the study in order to evaluate whether the combined therapy (metformin plus gliclazide) ameliorate or adversely effects on some cardiac protector markers of metformin among recently diagnosed patients with type 2 diabetes mellitus.Methods : A total number of 100 recently diagnosed patients with type 2 diabetes mellitus were enrolled in the present study from December 2014 until June 2015. Sixty eight patients completed the 12 weeks course of treatment; divided into two equal groups based on treatment regimen in which group1 treated with metformin and group2 treated with metformin plus gliclazide. Thirty two patients did not complete the course of the treatment for unknown reasons and considered as default. In addition to 31 healthy volunteers were randomly chosen and considered as Control Group. In which all the participants in the study underwent detection of blood pressure, pulse rate, weight, height & BMI in addition to the estimation of the levels of others biochemical analysis as glycemic indices, lipid profile & serum omentin - 1at the beginning of the study & after 12 weeks of treatment regimen.Results : The results of this study shown the beneficial amelioration of metformin on some markers that affect CVS represented as significant reduction in BMI (p<0.05), modest improvement in lipid profile with modest elevation in HDL level & lowering blood pressure, significant reduction in the levels of blood glucose & HbA1C (p<0.05), improves insulin sensitivity, reduced insulin resistance, and elevation of serum omentin - 1 level among newly diagnosed type 2 diabetic patients (group1). Furthermore, the results of current study are revealed that adding of gliclazide to metformin in treatment of type 2 diabetic patients might influence the documented beneficial effects of metformin on cardiovascular system at least by adversely changing the levels of serum omentin - 1 among group 2. Conclusions : Adding of gliclazide to metformin in treatment of patients with type 2 DM might extend the therapeutic action of metformin in regarding much better controlling of glycemic indices, insulin sensitivity and lipid profile. But, at the same time, it might attenuate some of beneficial effects of metformin on cardiovascular system at least by adversely influence on body weight and serum omentin - 1 levels.
